Your browser doesn't support javascript.
loading
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Mostafa, Sam; Rafizadeh, Reza; Polasek, Thomas M; Bousman, Chad A; Rostami-Hodjegan, Amin; Stowe, Robert; Carrion, Prescilla; Sheffield, Leslie J; Kirkpatrick, Carl M J.
Afiliación
  • Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
  • Rafizadeh R; MyDNA Life Australia Limited, Victoria, Australia.
  • Polasek TM; BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
  • Bousman CA; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
  • Rostami-Hodjegan A; Certara, Princeton, New Jersey, USA.
  • Stowe R; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Carrion P; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.
  • Sheffield LJ; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Kirkpatrick CMJ; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
CPT Pharmacometrics Syst Pharmacol ; 13(3): 424-436, 2024 03.
Article en En | MEDLINE | ID: mdl-38243630
ABSTRACT
Model-informed precision dosing using virtual twins (MIPD-VTs) is an emerging strategy to predict target drug concentrations in clinical practice. Using a high virtualization MIPD-VT approach (Simcyp version 21), we predicted the steady-state clozapine concentration and clozapine dosage range to achieve a target concentration of 350 to 600 ng/mL in hospitalized patients with treatment-resistant schizophrenia (N = 11). We confirmed that high virtualization MIPD-VT can reasonably predict clozapine concentrations in individual patients with a coefficient of determination (R2 ) ranging between 0.29 and 0.60. Importantly, our approach predicted the final dosage range to achieve the desired target clozapine concentrations in 73% of patients. In two thirds of patients treated with fluvoxamine augmentation, steady-state clozapine concentrations were overpredicted two to four-fold. This work supports the application of a high virtualization MIPD-VT approach to inform the titration of clozapine doses in clinical practice. However, refinement is required to improve the prediction of pharmacokinetic drug-drug interactions, particularly with fluvoxamine augmentation.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esquizofrenia / Antipsicóticos / Clozapina Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esquizofrenia / Antipsicóticos / Clozapina Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Australia